Evidence map›Paper›PMID 31852835›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions.

Steffen Rickelt, Charlene Condon, Miyeko Mana, Charlie Whittaker, Christina Pfirschke, Jatin Roper, Deepa T Patil, Ian Brown, Anthony R Mattia, Lawrence Zukerberg and 9 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. A comparison of artificial intelligence versus radiologists in the diagnosis of thyroid nodules using ultrasonography: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  8. Article
  9. Evolving pathologic concepts of serrated lesions of the colorectum.Journal of pathology and translational medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 3 countries.

Steffen RickeltDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. rohynes@mit.edu VDESHPANDE@mgh.harvard.edu srickelt@mit.edu.ORCID 0000-0002-5224-7764
Charlene CondonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Miyeko ManaDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-5516-4008
Charlie WhittakerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Christina PfirschkeCenter for Systems Biology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9434-4485
Jatin RoperDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0002-8851-1352
Deepa T PatilCleveland Clinic, Department of Pathology, Cleveland, Ohio.
Ian BrownEnvoi Pathology, Kelvin Grove, Queensland, Australia.
Anthony R MattiaDepartment of Pathology, North Shore Medical Center, Salem, Massachusetts.
Lawrence ZukerbergDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Qing ZhaoDepartment of Pathology and Laboratory Medicine, Boston University Medical Center, Boston, Massachusetts.
Runjan ChettyDepartment of Pathology, Toronto General Hospital, Toronto, Ontario, Canada.
Gregory Y LauwersDepartment of Pathology, Moffitt Cancer Center, Tampa, Florida.
Azfar NeyazDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Lieve G J LeijssenDepartment of General and Gastrointestinal Surgery, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-8633-6661
Katherine BoylanDepartment of Pathology, University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0001-9577-7813
Omer H YilmazDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Vikram Deshpande *Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. rohynes@mit.edu VDESHPANDE@mgh.harvard.edu srickelt@mit.edu.
Richard O Hynes *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. rohynes@mit.edu VDESHPANDE@mgh.harvard.edu srickelt@mit.edu.ORCID 0000-0001-7603-8396
Massachusetts Institute of Technology · USHarvard University · USBoston Medical Center · USCenter for Systems Biology · USCleveland Clinic · USHoward Hughes Medical Institute · USHuntsman Cancer Institute · USMoffitt Cancer Center · USNorth Shore Medical Center · USQueensland University of Technology · AUToronto General Hospital · CA

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Understanding and Improving Platinum Anticancer DrugsR01CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 1985 to 2018
$6.8M
Tumor-Stroma Interacions in the Tumor MicroenvironmentU54CA126515 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEINBERG, ROBERT A · 2006 to 2010
$6.5M
The Extracellular Matrix in Tumor Progression and MetastasisU54CA163109 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYNES, RICHARD O · 2011 to 2015
$3.7M
Impact of fasting on intestinal stem cells and cancerR01CA245314 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omer Yilmaz · 2020 to 2026
$2.3M
Dietary control of stem cells in physiology and cancerR01CA211184 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2017 to 2021
$2.0M
The role of Mtss1 in Hedgehog-mediated intestinal cancer stem cell functionK08CA198002 · NCI · TUFTS MEDICAL CENTER · PI ROPER, JATIN · 2015 to 2019
$845k
Howard Hughes Medical InstituteNCI NIH HHS K08 CA198002NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA034992NCI NIH HHS R01 CA211184NCI NIH HHS R01 CA245314NCI NIH HHS U54 CA126515NCI NIH HHS U54 CA163109
6 · The paper itself

Abstract

purposeSessile serrated lesions (SSL) are precursors to colon carcinoma, and their distinction from other polyps, in particular hyperplastic polyps (HP), presents significant diagnostic challenges. We evaluated expression patterns in colonic polyps of previously identified colon carcinoma-associated extracellular matrix (ECM) proteins to identify markers distinguishing SSLs from other polyps. EXPERIMENTAL

designGene-expression analyses of ECM proteins were performed using publicly available data on preneoplastic colonic polyps. In parallel, we evaluated by IHC the expression of agrin (AGRN) in over 400 colonic polyps, including HP, SSL with and without dysplasia, traditional serrated adenomas (TSA), and tubular adenomas (TA), and compared the consistency of standard histologic diagnosis of SSLs by experienced gastrointestinal pathologists with that of AGRN IHC.

resultsDifferential gene expression analysis and IHC identified AGRN, serine peptidase inhibitor (SERPINE2), and TIMP metallopeptidase inhibitor 1 (TIMP1) elevated in SSLs and HPs but decreased in TAs and absent in normal colon. AGRN-positive basal laminae were noted in all TA, TSA, HP, and SSL in distinguishable patterns, whereas other polyps and normal mucosa were negative. SSL with or without dysplasia consistently showed IHC staining for AGRN in the muscularis mucosae, which was absent in HP, TSA, TA, and other polyps. In contrast, histologic evaluation showed only weak interobserver agreement (kappa value = 0.493) in distinguishing SSLs.

conclusionsMuscularis mucosae-based AGRN immunostaining is a novel biomarker to distinguish SSL from HP, TSA, and TA, with a specificity of 97.1% and sensitivity of 98.9% and can assist in diagnosis of morphologically challenging colonic polyps.

Indexed as

Gene Expression Regulation, NeoplasticAdolescentAdultAgedAged, 80 and overAgrinBiomarkers, TumorChildChild, PreschoolColonic PolypsColorectal NeoplasmsDiagnosis, DifferentialHumansHyperplasiaMiddle AgedMucous MembraneAgrinBiomarkers, Tumor

Identifiers

PMID31852835
PMCPMC7073301
OpenAlexW2995708246

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.